Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS

We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF). Ruxolitinib interact...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavallai, Mehrad, Booth, Laurence, Roberts, Jane L., McGuire, William P., Poklepovic, Andrew, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951212/
https://www.ncbi.nlm.nih.gov/pubmed/26981780
http://dx.doi.org/10.18632/oncotarget.8039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951212/
https://www.ncbi.nlm.nih.gov/pubmed/26981780
http://dx.doi.org/10.18632/oncotarget.8039

Ejemplares similares